Company: NCEL
Filing Date: 2025-02-05
Form Type: F-3
Source: 0001213900-25-010223
Chunk: 14

Company: NewcelX Ltd.
Filing Date: 2025-02-05
Form: F-3
Chunk 14
---
 2025, we authorized and reserved sufficient Common Shares to satisfy the anti-dilution and ratchet rights of the Selling Shareholder under the October Debt SPA. We further issued to the Selling Shareholder in accordance therewith the entire amount of ratchet securities following the approval of certain items in NLS’s extraordinary general meeting on January 7, 2025, as follows: (i) 408,871 PPCs convertible into Common Shares, and (ii) 75,000 Common Shares. Corporate Information Our registered office and principal executive offices are located at The Circle 6, 8058 Zurich, Switzerland. Our telephone number in Switzerland is +41.44.512.2150. Our website address is https://nlspharma.com. The information contained on, or that can be accessed through, our website is not part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference. The SEC also maintains an Internet website that contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC. Our filings with the SEC are also available to the public through the SEC’s website at http://www.sec.gov.

<div align='center'>6</div>

KADIMASTEM BUSINESS Kadimastem is a clinical-stage pharmaceutical company focused on developing and manufacturing “off-the-shelf”, allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation of Human Embryonic Stem Cells, or hESCs, into functional cells. Kadimastem’s vision is to:

| ● | Replace, restore and repair                                                                                                          
 the functionality of diseased and malfunctioning cells in various degenerative diseases by transplantation of healthy and functional 
 cells; and                                                                                                                           |

| ● | Commercialize its proprietary                                                                                                              
 cell lines optimized for both the cure of diabetes and the treatment of Amyotrophic Lateral Sclerosis, or ALS, and other neurodegenerative 
 diseases, or NDDs.                                                                                                                         |

Kadimastem is primarily developing two products:

| 1. | AstroRx®, Kadimastem’s                                                                                                           
 lead product, which is an off-the-shelf cryopreserved cell therapy product in clinical development for the treatment for ALS and 
 in pre-clinical studies for other neurodegenerative indications. AstroRx® is comprised of fully differentiated astrocytes, which 
 are mainly cells that support the central nervous system, or CNS.                                                                |

| 2